Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1091283 | 0.73 | KDM4E (0.36) | CYP2A6PSMB8TSHR | |
| SCHEMBL2118528 | 0.67 | HPGD (0.31) | — | |
| SCHEMBL9399613 | 0.67 | MAOB (0.32) | — | |
| SCHEMBL11456159 | 0.67 | MAOA (0.34) | PSMB8 | |
| SCHEMBL4460823 | 0.67 | AHR (0.38) | PSMB8TSHR | |
| SCHEMBL621799 | 0.63 | TSHR (0.38) | TSHR | |
| SCHEMBL2118628 | 0.62 | MAOA (0.36) | CYP2A6PSMB8 | |
| SCHEMBL11642576 | 0.60 | MAPT (0.39) | TSHR | |
| SCHEMBL14775310 | 0.60 | ELANE (0.30) | — | |
| SCHEMBL3875623 | 0.60 | CALM1 (0.41) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1019378-B1 | HYPOGLYCEMIC AND HYPOLIPIDEMIC COMPOUNDS | LILLY CO ELI (US) | 2004-09-29 | — | — | EP | disclosed |
| US-20030225282-A1 | Enantioselective process for preparing arylated lactones and derivatives | ZHANG TONY YANTAO (US) | 2003-12-04 | — | — | US | disclosed |
| US-6617342-B1 | Treating hyperglycemia associated with non- insulin dependant diabetes and for treating hyperlipidemia. | ELI LILLY AND COMPANY | 2003-09-09 | — | — | US | disclosed |
| US-6617343-B1 | Treating non-insulin-dependent diabetes mellitus | ELI LILLY AND COMPANY | 2003-09-09 | — | — | US | disclosed |
| WO-2003031408-A2 | TRICYCLIC COMPOUNDS USEFUL FOR MODULATING LXR | ELI LILLY AND COMPANY (US) | 2003-04-17 | — | — | WO | disclosed |
| US-6541497-B1 | Amino acid derivatives of benzoxazin-2-ylaminoalkoxyphenylalkyl compounds | ELI LILLY AND COMPANY | 2003-04-01 | — | — | US | disclosed |
| EP-1286980-A2 | ENANTIOSELECTIVE PROCESS FOR PREPARING ARYLATED LACTONES AND DERIVATIVES | ELI LILLY AND COMPANY (US) | 2003-03-05 | — | — | EP | disclosed |
| EP-1214301-A1 | HYPOGLYCEMIC N,N-ARYLSULFONYLGLYCINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2002-06-19 | — | — | EP | disclosed |
| EP-1212304-A2 | HYPOGLYCEMIC SULFONYL PYRAZOLONES AND PYRAZOLINES | ELI LILLY AND COMPANY (US) | 2002-06-12 | — | — | EP | disclosed |
| US-6353027-B1 | ENANTIOMORPHIC AMINE DERIVATIVES FOR TREATMENT OF DIABETES | ELI LILLY AND COMPANY | 2002-03-05 | — | — | US | disclosed |
| EP-1019378-A4 | HYPOGLYCEMIC AND HYPOLIPIDEMIC COMPOUNDS | LILLY CO ELI (US) | 2001-09-26 | — | — | EP | disclosed |
| WO-2001016119-A1 | HYPOGLYCEMIC N,N-ARYLSULFONYLGLYCINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2001-03-08 | — | — | WO | disclosed |
| WO-2001016111-A2 | HYPOGLYCEMIC SULFONYL PYRAZOLONES AND PYRAZOLINES | ELI LILLY AND COMPANY (US) | 2001-03-08 | — | — | WO | disclosed |
| US-6194446-B1 | NON-INSULIN DEPENDENT DIABETES | ELI LILLY AND COMPANY | 2001-02-27 | — | — | US | disclosed |
| EP-0925063-A4 | HYPOGLYCEMIC AND HYPOLIPIDEMIC COMPOUNDS | LILLY CO ELI (US) | 2000-12-27 | — | — | EP | disclosed |
| US-6121282-A | 3-(CARBOXY, AMIDO, CYANO, OR HYDROXYAMINOCARBONYL)-6 OR 7-SUBSTITUTED-1,2,3,4-TETRAHYDROISOQUINOLINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2000-09-19 | — | — | US | disclosed |
| EP-1019378-A1 | HYPOGLYCEMIC AND HYPOLIPIDEMIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 2000-07-19 | — | — | EP | disclosed |
| EP-0925063-A1 | HYPOGLYCEMIC AND HYPOLIPIDEMIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 1999-06-30 | — | — | EP | disclosed |
| WO-1998000137-A1 | HYPOGLYCEMIC AND HYPOLIPIDEMIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 1998-01-08 | — | — | WO | disclosed |
| WO-1998000403-A1 | HYPOGLYCEMIC AND HYPOLIPIDEMIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 1998-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225282-A1 | Enantioselective process for preparing arylated lactones and derivatives | CYP51A1, AHR, LSS | CYP2A6 15/4885PSMB8 3405/4885TSHR 1595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.